Pirtobrutinib,Venetoclax,Rituximab
Eli Lilly,Roche,Abbvie
['pirto', 'valent ,(-prevalent)', 'valent ,(-prevalent),(-equivalent),(-bivalent)']
 finally the poor (relative to covalent btki) pfs dor explained vs the rosy picture by trial doctors. the cancer is already low level mutated from prior btki to develop resistance to pirtobrutinib. as always, cancer is the ultimate: whatever doesn't kill me makes me stronger.
New annonymous account because I'm not telling anyone about my diagnosis:
Mantle Cell Lymphoma Stage 4B P-53 mutation, 17P-, Ki-67 (50-70%).
Dying soon.